SU011248 (sunitinib)

DRUG2 trials

Sponsors

Pfizer, British Columbia Cancer Agency

Conditions

Carcinoma, Renal Cell MetastasisRelapsed or Cisplatin-Refractory Germ Cell Cancer

Phase 2

Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer

CompletedNCT00137423

PfizerCarcinoma, Renal Cell Metastasis

Start: 2005-05-31End: 2008-05-31Updated: 2009-09-30

Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer

CompletedNCT00371553

British Columbia Cancer AgencyRelapsed or Cisplatin-Refractory Germ Cell Cancer

Start: 2006-11-30End: 2009-06-30Updated: 2009-07-08

Related Papers

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.

2016-05-2624 citations

Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma.

2015-01-0761 citations

Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.

Journal of Clinical Oncology2014-02-014 citations

Heterogeneity of intermediate prognosis patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.

Journal of Clinical Oncology2014-02-01